N-phenyl-(homo)piperazinyl-benzenesulfonyl or benzenesulfonamide compounds suitable for treating disorders that respond to the modulation of the serotonin 5-HT

1. N-Phenyl-(homo)piperazinyl-benzenesulfonyl or benzenesulfonamide compounds of formula I

the stereoisomers, N-oxides, tautomers and/or physiologically tolerated acid addition salts thereof; and the compounds of the formula I, wherein at least one of the atoms has been replaced by its stable, non-radioactive isotope,

wherein

X is a bond or NR 4 ;

R 1 is selected from the group consisting of C 1 -C 4 -alkyl and fluorinated C 1 -C 4 -alkyl;

R 2 is selected from the group consisting of hydrogen and C 1 -C 4 -alkyl;

R 3 is selected from the group consisting of hydrogen, halogen, C 1 -C 4 -alkyl, fluorinated C 1 -C 4 -alkyl, C 1 -C 4 -alkoxy and fluorinated C 1 -C 4 -alkoxy;

R 4 is selected from the group consisting of hydrogen, C 1 -C 4 -alkyl and fluorinated C 1 -C 4 -alkyl;

R 5 is a group -A-[O—B] p —O—R 7 , wherein

A and B are independently of each other C 1 -C 4 -alkylene or fluorinated C 1 -C 4 -alkylene;

R 7 is C 1 -C 4 -alkyl or fluorinated C 1 -C 4 -alkyl; and

p is 0, 1, 2, 3, 4, 5 or 6;

R 6 is selected from the group consisting of halogen, C 1 -C 2 -alkyl, fluorinated C 1 -C 2 -alkyl, C 1 -C 2 -alkoxy and fluorinated C 1 -C 2 -alkoxy;

m is 0, 1 or 2; and

n is 1 or 2.

2. The compounds of claim 1 , where A is C 1 -C 2 -alkylene.

3. The compounds of claim 2 , where A is methylene (CH 2 ) or 1,1-ethylene [CH(CH 3 )].

4. The compounds of claim 1 , where B is C 2 -C 3 -alkylene.

5. The compounds of claim 1 , where p is 0.

6. The compounds of claim 1 , where R 7 is C 1 -C 2 -alkyl or fluorinated C 1 -C 2 -alkyl.

7. The compounds claim 1 , where R 5 is selected from the group consisting of C 1 -C 2 -alkoxy-methyl, 1-(C 1 -C 2 -alkoxy)-ethyl, (fluorinated C 1 -C 2 -alkoxy)-methyl and 1-(fluorinated C 1 -C 2 -alkoxy)-ethyl and is preferably methoxymethyl, ethoxymethyl, 2,2,2-trifluoroethoxymethyl or 1-methoxyethyl.

8. The compounds of claim 1 , where R 5 is bound in the 2- or 3-position, relative to the 1-position of the sulfonylamino group SO—NR 4 .

9. The compounds of claim 1 , where R 1 is C 1 -C 4 -alkyl.

10. The compounds of claim 1 , where R 2 is hydrogen.

11. The compounds of claim 1 , where R 3 is selected from the group consisting of methoxy, ethoxy, methyl and ethyl and is preferably methoxy, ethoxy or methyl.

12. The compounds of claim 1 , where X is NR 4 .

13. The compounds of claim 1 , where R 4 is hydrogen or C 1 -C 4 -alkyl, preferably hydrogen or methyl.

14. The compounds of claim 1 , where R 6 is selected from the group consisting of F, Cl, methyl, difluoromethyl, trifluoromethyl, methoxy, difluoromethoxy and trifluoromethoxy.

15. The compounds of claim 1 , where m is 0.

16. The compounds of claim 1 , where n is 1.

17. The compounds of claim 1 , wherein at least one hydrogen atom has been replaced by a deuterium atom.

18. A pharmaceutical composition comprising at least one compound of claim 1 , a stereoisomer, N-oxide, tautomer and/or physiologically tolerated acid addition salt thereof, and at least one physiologically acceptable carrier and/or auxiliary substance.

19. The compounds of claim 1 , where R 1 is methyl.

20. The compounds of claim 1 or the stereoisomers, N-oxides, tautomers or physiologically tolerated acid addition salts thereof, selected from the group consisting of:

4-Methoxy-N-(3-methoxymethyl-phenyl)-3-(4-methyl-piperazin-1-yl)-benzenesulfonamide hydrochloride;

N-(2-Methoxymethyl-phenyl)-4-ethoxy-3-(4-methyl-piperazin-1-yl)-benzenesulfonamide hydrochloride;

N-(3-Methoxymethyl-phenyl)-4-ethoxy-3-(4-methyl-piperazin-1-yl)-benzenesulfonamide hydrochloride;

N-(3-Methoxymethyl-phenyl)-4-methyl-3-(4-methyl-piperazin-1-yl)-benzenesulfonamide hydrochloride;

N-(2-Methoxymethyl-phenyl)-4-methoxy-3-(4-methyl-piperazin-1-yl)benzenesulfonamide hydrochloride; and

N-(2-Methoxymethyl-phenyl)-4-methyl-3-(4-methyl-piperazin-1-yl)-benzenesulfonamide hydrochloride.